Journal of Yeungnam Medical Science

영남대 의대 학술지 편집위원회 (Yeungnam University College of Medicine, Yeungnam University Institute Medical Science)
권호 표지
DOI QR코드

DOI QR Code

Effective and appropriate use of weight loss medication in pediatric obesity: a narrative review

  • Yoojin Lindsey Chung (Department of Pediatrics, Korea University Ansan Hospital, Korea University College of Medicine)
  • 투고 : 2024.04.04
  • 심사 : 2024.05.27
  • 발행 : 2024.07.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Over the past few decades, there has been a notable increase in the incidence of pediatric obesity, which is a significant public health concern. Children who are obese have a greater risk of type 2 diabetes, hypertension, dyslipidemia, polycystic ovary syndrome, obstructive sleep apnea, and adult obesity. Lifestyle modification therapy is typically the initial approach to treat pediatric obesity. For patients who do not achieve success with lifestyle modification therapy alone, pharmacotherapy is the next logical treatment option. When selecting an anti-obesity medication (AOM), it is essential to first ascertain the medical background of the patient, including current medications and obesity-associated comorbidities. Evaluation of obesity phenotypes in patients may also be beneficial. AOMs for pediatric obesity include metformin, orlistat, glucagon-like peptide 1 agonists, phentermine, and the phentermine/topiramate combination. Sufficient lifestyle modification therapy should be administered before considering pharmacotherapy and continued after the initiation of AOM. To ensure healthy development, monitoring growth and puberty development during anti-obesity treatments is essential.

키워드

참고문헌

  1. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet 2017;390:2627-42.
  2. Kim JH, Moon JS. Secular trends in pediatric overweight and obesity in Korea. J Obes Metab Syndr 2020;29:12-7.
  3. Yoo SE, Lee JH, Lee JW, Park HS, Lee HA, Kim HS. Increasing prevalence of fasting hyperglycemia in adolescents aged 10-18 years and its relationship with metabolic indicators: the Korea National Health and Nutrition Examination Study (KNHANES), 2007-2018. Ann Pediatr Endocrinol Metab 2022;27:60-8.
  4. Park HK, Lim JS. Change of obesity prevalence and lifestyle patterns before and during COVID-19 among Korean adolescents. Ann Pediatr Endocrinol Metab 2022;27:183-91.
  5. Kang S, Seo MY, Kim SH, Park MJ. Changes in lifestyle and obesity during the COVID-19 pandemic in Korean adolescents: based on the Korea Youth Risk Behavior Survey 2019 and 2020. Ann Pediatr Endocrinol Metab 2022;27:281-8.
  6. Kim M, Kim J. Cardiometabolic risk factors and metabolic syndrome based on severity of obesity in Korean children and adolescents: data from the Korea National Health and Nutrition Examination Survey 2007-2018. Ann Pediatr Endocrinol Metab 2022;27:289-99.
  7. Abbasi A, Juszczyk D, van Jaarsveld CH, Gulliford MC. Body mass index and incident type 1 and type 2 diabetes in children and young adults: a retrospective cohort study. J Endocr Soc 2017;1:524-37.
  8. Turer CB, Brady TM, de Ferranti SD. Obesity, hypertension, and dyslipidemia in childhood are key modifiable antecedents of adult cardiovascular disease: a call to action. Circulation 2018;137:1256-9.
  9. Wuhl E. Hypertension in childhood obesity. Acta Paediatr 2019;108:37-43.
  10. Vos MB, Abrams SH, Barlow SE, Caprio S, Daniels SR, Kohli R, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr 2017;64:319-34.
  11. Styne DM, Arslanian SA, Connor EL, Farooqi IS, Murad MH, Silverstein JH, et al. Pediatric obesity-assessment, treatment, and prevention: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2017;102:709-57.
  12. Hampl SE, Hassink SG, Skinner AC, Armstrong SC, Barlow SE, Bolling CF, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics 2023;151:e2022060640.
  13. Kim JH, Lim JS. Prevalence trends of metabolic syndrome among Korean children and adolescents from a population-based cross-sectional survey. Life (Basel) 2022;12:1404.
  14. US Preventive Services Task Force; Grossman DC, Bibbins-Domingo K, Curry SJ, Barry MJ, Davidson KW, et al. Screening for obesity in children and adolescents: US Preventive Services Task Force recommendation statement. JAMA 2017;317:2417-26.
  15. Srivastava G, Fox CK, Kelly AS, Jastreboff AM, Browne AF, Browne NT, et al. Clinical considerations regarding the use of obesity pharmacotherapy in adolescents with obesity. Obesity (Silver Spring) 2019;27:190-204.
  16. Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015;100:342-62.
  17. Lenders CM. Paediatric obesity: can medications help. Curr Opin Endocrinol Diabetes Obes 2015;22:331-9.
  18. O'Hara V, Cuda S, Kharofa R, Censani M, Conroy R, Browne NT. Clinical review: guide to pharmacological management in pediatric obesity medicine. Obes Pillars 2023;6:100066.
  19. Cuda S, Censani M, Kharofa R, O'Hara V, Conroy R, Williams DR, et al. Medication-induced weight gain and advanced therapies for the child with overweight and obesity: an Obesity Medicine Association (OMA) Clinical Practice Statement 2022. Obes Pillars 2022;4:100048.
  20. Tondt J, Bays HE. Concomitant medications, functional foods, and supplements: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obes Pillars 2022;2:100017.
  21. Hershey AD, Powers SW, Nelson TD, Kabbouche MA, Winner P, Yonker M, et al. Obesity in the pediatric headache population: a multicenter study. Headache 2009;49:170-7.
  22. Oakley CB, Scher AI, Recober A, Peterlin BL. Headache and obesity in the pediatric population. Curr Pain Headache Rep 2014;18:416.
  23. Acosta A, Camilleri M, Abu Dayyeh B, Calderon G, Gonzalez D, McRae A, et al. Selection of antiobesity medications based on phenotypes enhances weight loss: a pragmatic trial in an obesity clinic. Obesity (Silver Spring) 2021;29:662-71.
  24. Corcoran C, Jacobs TF. Metformin [updated 2023 Aug 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Apr 4]. https://www.ncbi.nlm.nih.gov/books/NBK518983/.
  25. O'Connor EA, Evans CV, Burda BU, Walsh ES, Eder M, Lozano P. Screening for obesity and intervention for weight management in children and adolescents: evidence report and systematic review for the US Preventive Services Task Force. JAMA 2017;317:2427-44.
  26. Yanovski JA, Krakoff J, Salaita CG, McDuffie JR, Kozlosky M, Sebring NG, et al. Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial. Diabetes 2011;60:477-85.
  27. Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005;293:2873-83.
  28. Ozkan B, Bereket A, Turan S, Keskin S. Addition of orlistat to conventional treatment in adolescents with severe obesity. Eur J Pediatr 2004;163:738-41.
  29. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000;320:1240-3.
  30. Kelly AS, Metzig AM, Rudser KD, Fitch AK, Fox CK, Nathan BM, et al. Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study. Obesity (Silver Spring) 2012;20:364-70.
  31. Kelly AS, Rudser KD, Nathan BM, Fox CK, Metzig AM, Coombes BJ, et al. The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial. JAMA Pediatr 2013;167:355-60.
  32. Weghuber D, Forslund A, Ahlstrom H, Alderborn A, Bergstrom K, Brunner S, et al. A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity. Pediatr Obes 2020;15:e12624.
  33. Kelly AS, Auerbach P, Barrientos-Perez M, Gies I, Hale PM, Marcus C, et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med 2020;382:2117-28.
  34. Weghuber D, Barrett T, Barrientos-Perez M, Gies I, Hesse D, Jeppesen OK, et al. Once-weekly semaglutide in adolescents with obesity. N Engl J Med 2022;387:2245-57.
  35. Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne) 2019;10:155.
  36. Lau J, Bloch P, Schaffer L, Pettersson I, Spetzler J, Kofoed J, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem 2015;58:7370-80.
  37. Lyseng-Williamson KA. Glucagon-like peptide-1 receptor analogues in type 2 diabetes: their use and differential features. Clin Drug Investig 2019;39:805-19.
  38. Ryder JR, Kaizer A, Rudser KD, Gross A, Kelly AS, Fox CK. Effect of phentermine on weight reduction in a pediatric weight management clinic. Int J Obes (Lond) 2017;41:90-3.
  39. Kelly AS, Bensignor MO, Hsia DS, Shoemaker AH, Shih W, Peterson C, et al. Phentermine/topiramate for the treatment of adolescent obesity. NEJM Evid 2022;1:10.1056/evidoa2200014.
  40. Mital S, Nguyen HV. Cost-effectiveness of antiobesity drugs for adolescents with severe obesity. JAMA Netw Open 2023;6:e2336400.
  41. CONTRAVE package insert revised 9/2014 (naltrexone HCl and bupropion HCl) extended-release tablets. La Jolla, CA: Orexigen Therapeutics, Inc; 2014.
  42. Markham A. Setmelanotide: first approval. Drugs 2021;81:397-403.
  43. Kievit P, Halem H, Marks DL, Dong JZ, Glavas MM, Sinnayah P, et al. Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques. Diabetes 2013;62:490-7.
  44. Chen KY, Muniyappa R, Abel BS, Mullins KP, Staker P, Brychta RJ, et al. RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals. J Clin Endocrinol Metab 2015;100:1639-45.
  45. Clement K, van den Akker E, Argente J, Bahm A, Chung WK, Connors H, et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol 2020;8:960-70.
  46. Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023;402:613-26.
  47. Gadde KM, Atkins KD. The limits and challenges of antiobesity pharmacotherapy. Expert Opin Pharmacother 2020;21:1319-28.